# Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

> **NCT01453088** · PHASE2 · TERMINATED · sponsor: **Hackensack Meridian Health** · enrollment: 63 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Melphalan
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT01453088
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06-24
- **Primary completion:** 2022-05-01
- **Final completion:** 2022-05-01
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** Lack of Accrual
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453088, "Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01453088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*